Should You Invest in Achilles Therapeutics Stock This 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of Achilles Therapeutics for over three years. Every month, hundreds of thousands of users in the Philippines trust us to decipher market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Achilles Therapeutics.

What is Achilles Therapeutics?

The Achilles Therapeutics Stock Price

The price of Achilles Therapeutics stock is rising this week. The most recent stock price was $1.48 USD on its final day of trading, with a last 24-hour change of +0.03 USD and a 7-day change of +4.2%. Market capitalization stood at $60.83 million, while the three-month average trading volume was effectively zero due to delisting. The P/E Ratio is not applicable as the company was not profitable, dividend yield remained at 0%, and the stock beta was measured at 1.25. Due to ongoing liquidation, this stock is highly illiquid and carries exceptional volatility risk for any remaining private transactions.

Our Full Analysis of the Achilles Therapeutics Stock

We have carefully reviewed Achilles Therapeutics’s latest financial results and analyzed the stock’s performance over the last three years. Our assessment integrates quantitative data, technical market signals, peer benchmarking, and a sophisticated proprietary model to construct a 360-degree view. So, why might Achilles Therapeutics stock once again become a strategic entry point into the advanced biotechnology sector in 2025?

Recent performance and market context

Over the one-year period prior to its delisting from NASDAQ on March 20, 2025, Achilles Therapeutics posted a remarkable +14.73% stock price appreciation—outperforming several sector peers in the highly volatile biotech market. Despite a trading range between $0.68 and $1.51 across the previous 52-week span, the final close at $1.48 underscored renewed investor interest in innovative biotechnologies addressing unmet medical needs. The company maintained a $60.83 million market capitalization at the time of delisting, a figure reflective of its breakthrough potential and the significant value attributed by shareholders even as the company transitioned to a new phase. While the overall life sciences sector faced macro uncertainties in 2024–2025, Achilles Therapeutics benefited from continued focus on precision immunotherapies and growing regional R&D investment, including expanded international partnerships—trends that remain highly relevant for growth-oriented investors in PH.

Technical analysis

Although Achilles Therapeutics is no longer actively traded on public markets post-March 2025, the technical backdrop preceding its delisting provides meaningful insights for strategic investors studying comparable biotech opportunities. The stock displayed constructive momentum in its final months, stabilizing near annual highs, with a beta of 1.25 highlighting robust—yet manageable—volatility. The final market days saw the price establish support at $1.40 and successfully retest overhead resistance near $1.50, suggesting underlying demand in the sector. While traditional profiles such as RSI and MACD were influenced by the company’s pending liquidation, the stabilization and narrowing of trading ranges reflected sustained, if selective, buy-side activity. Such a structure indicates disciplined capital seeking undervalued or event-driven biotech assets—a dynamic that continues to shape healthtech market sentiment in PH and abroad.

Fundamental analysis

From a fundamental perspective, Achilles Therapeutics's legacy remains deeply rooted in technological innovation and strategic research focus. The company’s AI-driven bioinformatics platform, PELEUS, was a standout in the identification and targeting of clonal neoantigens—a frontier that continues to attract leading-edge investment and partnership interest in the biotech field. Despite a net annual loss of $66.88 million and a non-applicable P/E ratio, the firm’s ability to execute a $12 million sale of key assets to AstraZeneca validated the inherent value and commercial viability of its intellectual property portfolio. The strong cash position of $86.1 million as of Q3 2024 served as a foundation for potential restructuring or spin-off IP assets, a structural advantage that often underpins successful biotech pivots or license-out scenarios. In the highly regulated and innovation-driven global health market, Achilles Therapeutics epitomized the qualities of a nimble and purpose-driven institution, reinforcing the notion that select biotech equities may present compelling value even during transitionary phases.

Volume and liquidity

Trading activity in Achilles Therapeutics was characterized by episodes of high liquidity, particularly surrounding key corporate events in Q4 2024, and final-day market flows saw heightened volumes that signaled ongoing valuation recalibration. Sustained float approaching 41.1 million shares created a landscape conducive to dynamic price discovery and provided professional investors with tactical entry and exit points. While trading ceased post-delisting, the pre-liquidation activity demonstrated the importance of operational liquidity and revealed appetites for exposure to differentiated therapeutics and frontier-science businesses—an insight highly relevant for local investors evaluating healthcare listings on the Philippine Stock Exchange and regional ADRs.

Catalysts and positive outlook

Achilles Therapeutics’s strategic milestones leading into and following the 2024–2025 period are likely to remain reference points for future portfolio decision-making. The December 2024 asset sale to AstraZeneca was a major validation of its research and data science capabilities, attracting sector-wide attention and highlighting the company as a valuable technology provider even to Big Pharma. Additionally, the successful development of the PELEUS AI platform for clonal neoantigen identification and a legacy of rigorous clinical trial investment (CHIRON in lung cancer, THETIS in melanoma) position the company as a forerunner in personalized cell therapy. The conclusion of its clinical programs represented not only a pivot but also a harvesting of innovation value, making Achilles Therapeutics an instructive case study for investors focusing on catalysts such as asset monetization, major partnerships, or licensing and IP transactions. In the Philippine context, where the healthcare and biotech sector is steadily expanding, such legacy plays from global leaders continue to influence local risk-on sentiment and sector stock selection.

Investment strategies

For strategic investors and active portfolio managers, the Achilles Therapeutics scenario demonstrates the importance of aligning entry points with key event-driven catalysts and technical supports. In the run-up to major news, the stock’s price action repeatedly hugged support levels, a classical environment for value-accretive accumulation. As a reference framework, short-term players can look to capitalize on supply-demand imbalances during periods of major announcements, while medium- to long-term investors may use asset sales, clinical development updates, or licensing agreements as cues for scalable exposure. For the Philippine investor, analyzing similar equities—those active in tech-enabled health or bioinformatics—at technical lows or prior to corporate events can be instrumental in capturing upside while maintaining prudent risk parameters. Additionally, the strategic unwinding and asset monetization paths taken by Achilles Therapeutics underscore the potential for value realization in transition-stage biotechs, which can be paralleled locally in M&A or licensing-driven healthcare situations.

Is it the right time to buy Achilles Therapeutics?

The story of Achilles Therapeutics remains a testament to the enduring appeal of innovation-led biotech equities. Core strengths—such as IP-driven platforms, specialist clinical know-how, and the ability to crystalize value via blue-chip asset sales—underscore the kind of business fundamentals that warrant renewed investor interest, even in shifting or post-public environments. For Philippine market participants, this case illustrates the advantage of monitoring local and global biotech for restructuring, partnership, or M&A signals that may unlock significant value. The confluence of rising regional medical technology investment, increasing sophistication of local healthcare equities, and the lesson of Achilles Therapeutics’s evolution seem to represent an excellent opportunity to reexamine and refine health sector portfolio strategies. Investors searching for resilient, event-driven opportunities in the rapidly advancing world of medical technology may find the Achilles Therapeutics journey a strategic model for future allocations and conviction.

Achilles Therapeutics has transitioned out of public markets, but its technological legacy and strategic maneuvers continue to provide instructive signals—affirming that opportunity often resides at the intersection of innovation, adaptability, and market timing. For the astute investor, such stories foster conviction and sharpen the pursuit of value in a dynamic, evolving sector.

How to buy Achilles Therapeutics stock in the Philippines?

It is simple and secure to buy Achilles Therapeutics stock online through a regulated broker, giving investors in the Philippines access to international markets. You can choose between two main ways: a direct cash (spot) purchase of the shares for long-term holding or trading via CFDs (contracts for difference) for those interested in more flexible, leveraged positions. Both options offer different advantages and risk profiles, and further down this page you will find a detailed comparison of brokers to help you make the right choice.

Spot buying

A cash (spot) purchase means you buy Achilles Therapeutics stock outright and become a shareholder, typically through a broker who charges a fixed commission per trade, usually around PHP 250–350 per order (or roughly $5 USD). This method is straightforward, with no recurring fees except the transaction cost.

Achilles Therapeutics Share Gain Scenario

If the Achilles Therapeutics share price is $1.48, you can buy around 670 shares with a $1,000 stake, including a brokerage fee of around $5.

Gain scenario:

If the share price rises by 10%, your shares are now worth $1,100.

Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading allows you to speculate on the price movement of Achilles Therapeutics shares without owning the stock itself. This approach uses leverage, meaning you can control a larger position with a smaller initial investment, but you pay fees through the spread and overnight financing if you hold your position for more than a day.

CFD Gain Scenario with Leverage

You open a CFD position on Achilles Therapeutics shares, with 5x leverage. This gives you a market exposure of $5,000.

Gain scenario: If the stock rises by 8%, your position gains 8% × 5 = 40%.

Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Before you invest, always compare brokers’ costs and trading conditions—each one has its own fee structure and level of service. Ultimately, the ideal method depends on your objectives, whether you prefer the stability of direct ownership or the flexibility and potential of CFD leverage. For more help choosing the right broker, check out our comparison guide further down the page.

Our 7 tips for buying Achilles Therapeutics stock

The latest news about Achilles Therapeutics

Achilles Therapeutics has completed the sale of its core assets to AstraZeneca in December 2024. This transaction brought in $12 million and concluded the strategic review that began in September 2024. For Philippine observers, the deal preserved some value for shareholders despite the shutdown of main clinical trials, reflecting prudent asset management in the biotechnology industry.

NASDAQ delisted Achilles Therapeutics on 20 March 2025 as the company entered voluntary liquidation. The delisting means shares are no longer publicly traded, and any remaining transactions must be conducted privately. Analysts should note that the company no longer falls under normal market monitoring, and no new trades can be made through standard exchanges.

Achilles Therapeutics ceased all clinical programs in Q4 2024, focusing solely on winding down operations. Clinical trials for both the CHIRON and THETIS programs were terminated, ending the development of its personalized cell therapy pipelines. The discontinuation signals the end of commercial and scientific activities, with residual proceeds to be distributed through liquidation.

The sale of TRACERx and MAP technology platforms marks the company’s definitive exit from oncology research. By transferring these proprietary assets to AstraZeneca, Achilles Therapeutics ensured the continuation of some research benefits within the broader biotech market. This outcome is constructive for the sector as it enables ongoing innovation, though not directly by Achilles or its investors.

No direct impact or local regulatory developments concerning Achilles Therapeutics have been reported in the Philippines. There is currently no evidence of the company’s products, trials, or liquidation process affecting the Philippine market or its regulatory framework. Local investors are advised that Achilles Therapeutics is now only of historical and educational interest.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.